RPG Life Sciences Q1 FY27 Revenue up 15.8% to ₹195.7 Cr; EBITDA grows 17.9%
RPG Life Sciences reported Q1 FY27 revenue of ₹195.7 Cr, a 15.8% increase year-on-year. EBITDA grew 17.9% to ₹48.0 Cr, with margins expanding to 24.5%. Domestic Formulations grew 14.8%, outpacing the market. The company entered the Top 50 Indian Pharma Companies list.
The results show robust growth and market outperformance, which is positive for the company. However, the impact is medium as it concerns quarterly results and does not involve extraordinary corporate actions like mergers, acquisitions, or significant fundraising that would have a higher immediate impact.
The company reported strong financial results with significant year-on-year growth in revenue and EBITDA, alongside margin expansion. Outperformance in domestic formulations and positive commentary from the Managing Director indicate a favorable business outlook.
RPG Life Sciences Limited announced its unaudited financial results for the quarter ended June 30, 2026, reporting a revenue growth of 15.8% to ₹195.7 crore, up from ₹168.9 crore in the same quarter last year.
EBITDA for the quarter increased by 17.9% to ₹48.0 crore, with EBITDA margins improving by 40 basis points to 24.5% compared to 24.1% in Q1 FY26. This margin expansion is attributed to operating discipline, strategic launches, field-force effectiveness, and a focus on key therapies.
The company's Domestic Formulations business showed strong momentum, growing at 14.8%, outperforming the Indian pharma market growth rate of 11.6%. The International Formulations segment registered 7.7% growth, and the API business delivered a significant 35.6% growth.
Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., commented that the company has started FY27 with healthy growth and profitability, continuing its track record of market-beating performance. He highlighted the company's entry into the Top 50 Indian pharmaceutical companies as an important milestone. Looking ahead, the focus remains on strengthening international presence and scaling up API operations.
Other achievements during the quarter include Naprosyn growing at 16%, recognition as ‘Top Nephrology Company- 2026’, ‘Best Use of AI in Sales Force Effectiveness’, and ‘Excellence in Breakthrough Pharmaceutical Innovations’.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.